BAT Korea Halves Prices of New Heated Tobacco Products

May.05.2023
BAT Korea Halves Prices of New Heated Tobacco Products
British American Tobacco (BAT) cuts prices by 50% for its new product in South Korea to increase pod sales, raising concerns over its long-term profitability.

Recently, according to a report from South Korean media outlet "Today's Economy," British American Tobacco (BAT) Korea has cut the price of their new heated but not burned product by half, within two months of its launch. The move is an attempt by BAT to boost sales of their pod product by offering lower prices. However, with decreasing profitability, the market is becoming increasingly skeptical about the long-term viability of this share-focused strategy.


Starting from April 17th, BAT is selling Glo Hyper X2 at a 50% discount off the original price. Although it is promoted as a sales campaign, it will continue until June 8th, which is essentially a price reduction.


Comparison of prices for non-burning products in the South Korean market | Graphic by 2FIRSTS.


BAT is increasing its market share through continuous promotional activities.


In 2021, the company offered a 90% discount on the price of the product Glo, selling it for 9,500 Korean won during a three-week pre-sale period. Subsequently, the company continued to sell the product at the same discounted rate throughout the year through several promotional events.


The "Glo Pro Slim" continued the promotional campaign when it was subsequently released.


KT&G and PMI Korea dominate the heated tobacco products market in South Korea with approximately 40% market share each. However, BAT's low pricing strategy has led to an increase in their market share. According to BAT, their market share has jumped from 6.04% in 2020 to 11.72% last year.


South Korean financial media outlet "Today's Finance" believes that the strategy of BAT is to generate actual revenue by introducing exclusive replacement pods. They initially used universal pods, but now have launched promotion-specific pods that are not compatible with other non-combustible heating products under their umbrella.


The idea is that the more users a product has, the greater its pod sales volume will be.


Dual Decline of Profits and Profit Margins


However, analysts have stated that this strategy is leading to a deterioration in the profitability of BAT.


Last year, South Korean BAT companies saw a 14.3% increase in revenue, reaching 539.8 billion Korean won, but operating profits decreased by 11.9% to 44.6 billion Korean won. Operating profit margins also declined from 10.7% to 8.3%. However, as the company did not disclose the performance of its South Korean subsidiary, Rothman's SpiceVibe, the specific amount of losses is still unclear.


The tobacco industry believes that the price threshold for low-end heated non-burning products is between 30,000 and 40,000 Korean won in order to maintain profit margins.


Once the selling price drops below this price, it means a loss in terms of cost.


An industry expert states:


This is a nascent market that only holds a 15% share of the entire tobacco market, hence a product expansion strategy may prove effective.


However, "BAT (Baidu, Alibaba, and Tencent) will find it difficult to continue bearing the losses generated by promotions and low-priced products.


Regarding this matter, a spokesperson for BAT stated, "We will focus on product sales in order to establish our position in the heated non-combustion market.


Related Reading:


PMI (Philip Morris International) teams up with KT&G (Korea Tobacco & Ginseng Corporation) to seize the global market, as BAT (British American Tobacco) aims to attract Korean customers through low pricing strategies.


KT&G and PMI compete for market leadership in South Korea.


The PMI profits of the South Korean market have increased by 163%, while BAT has experienced a decline of 12%.


ELFBAR, a South Korean agent, has reported an increase in initial orders and is aiming to sell 2 million units in South Korea this year.


South Korea may abandon the tax increase on HNB, which currently has a tax rate of 90.4% of regular cigarettes.


Reference/source:


Half-price just two months after release...How long will BAT's e-cigarette expansion strategy continue?



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Capital is reassessing the global tobacco and modern nicotine industry as heated tobacco, vaping and nicotine pouches reshape demand, profitability and regulation. At the 2026 New Approaches Summit in New York, investors and analysts examined whether smoke-free growth can sustain earnings, how regulation shapes startup value, and whether shareholder engagement can be more effective than divestment. The debate points to a broader shift: tobacco transition is increasingly becoming a capital-allocation, governance and valuation question.
Capital Markets
Oct.05
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Pennsylvania Vape Directory Law Survives Court Challenge From Nova Distro and Others Amid Similar Rulings Across States
Pennsylvania Vape Directory Law Survives Court Challenge From Nova Distro and Others Amid Similar Rulings Across States
A U.S. federal court upheld Pennsylvania's vape directory law on October 14, rejecting a challenge brought by Nova Distro, 101 Distributors and companies operating Tobacco Hut retail stores. Court records show that vaping accounts for about 60% of Tobacco Hut's profits and that the chain held approximately $2 million in inventory potentially subject to seizure under the law as of June 2. Pennsylvania began enforcement on October 19. The ruling follows similar appellate decisions in other states, even as new research shows that unlisted vaping products continue to account for substantial sales in states with established directories.
Regulations
Oct.22